Ceruzzi Properties Secures $350 Million Loan at ‘The Centrale’ NYC Luxury Tower

New loan from Meritz Securities marks the first Korean inventory loan in New York City

NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) — Ceruzzi Properties has secured the next phase of financing at The Centrale, the luxury residential condominium tower at 138 East 50th Street in the Midtown East neighborhood of Manhattan.

Meritz provided Ceruzzi with a $350 million inventory loan collateralized by the luxury residential tower, which pays off a previous $300 million construction loan Madison Realty Capital provided to Ceruzzi in 2017. The new financing marks the first Korean inventory loan in New York City.

“We are pleased with the seamless execution of this latest financing between all parties involved,” said Ceruzzi President Arthur Hooper. “In addition, we are very appreciative of the original construction loan that Madison Realty Capital provided on the property, which allowed us to complete this remarkable asset within the original timeline.”

The 803-foot, 63-floor tower features 124 luxury residential condominium units, 8,527 square feet of retail space at and below grade, and a 25-space parking garage, with a façade designed by Pelli Clarke Pelli Architects. Ceruzzi completed The Centrale in early 2019 and has begun selling condos at the project, having put 20 units into hard contract already.

VI Development Group advised Meritz on the transaction and tapped PIA Asset Management to enter as the asset management company for the project.

“We’ve always had great confidence in this borrower and this asset,” said Terence Park, CEO and President of VI Development Group. “The transaction shows that Korean investors have rapidly developed their underwriting abilities in recent years, putting them on par with major local lenders. We believe this is just the beginning of an influx of sophisticated Korean capital that will provide an attractive alternative financing option for New York City borrowers moving forward.”

The new financing pays off the $300 million construction loan Madison Realty Capital provided to Ceruzzi in 2017 and allows the firm to successfully exit the investment.

“It’s been a pleasure working with a top-tier sponsor such as Ceruzzi Properties and the firm’s partners throughout this process,” said Josh Zegen, Co-Founder and Managing Principal of Madison Realty Capital. “We are proud to have played a significant role in bringing this stunning, high-quality asset to fruition.”

JLL represented Ceruzzi exclusively on the transaction.

“‎New York City remains the go-to market for global capital,” said JLL Managing Director Chris Peck. “This transaction proves that quality product and premier sponsorship, coupled with a central location, will always drive liquidity for condo inventory financing.”

The Centrale offers a mix of efficient one- to five-bedroom units, ranging from 777 square feet to 5,388 square feet. The building features luxury amenities including an indoor pool and spa, fitness center, and shared work areas, while interior design by Champalimaud Design contributes to the property’s overall high-end sheen.

The property is located in the Midtown East’s Plaza District, between Third Avenue and Lexington Avenues. The high-end location offers easy access to Grand Central and its range of subway trains, including the 4, 5, 6, 7 and S, as well as uptown, downtown and crosstown buses, and close proximity to nearby attractions such as Times Square and Bryant Park.

About Madison Realty Capital (MRC)
Madison Realty Capital (MRC) is a New York City based real estate private equity firm focused on debt and equity investment strategies with regional offices in key markets including Los Angeles and Dallas. Founded in 2004, MRC has closed on approximately $12 billion of transactions in the multifamily, retail, office, industrial and hotel sectors. The firm manages investments in the United States on behalf of a global investor base. MRC is a fully integrated firm with over 60 employees across all real estate investment, development, and property management disciplines. Among other industry recognitions, MRC has been named to the Commercial Observer’s prestigious “Power 100” list of New York City real estate players and is consistently cited as one of the industry’s top construction lenders.

Media inquiries, contact
Great Ink Communications: (212) 741-2977
Tom Nolan –  tom@greatink.com

Meltwater Announces Podcast Monitoring Integration

SAN FRANCISCO, Feb. 20, 2020 (GLOBE NEWSWIRE) — Meltwater, a global leader in media intelligence, today announces the addition of podcast monitoring into their product suite, giving customers the ability to monitor 25,000 podcasts globally in real-time.

In 2019, over half of all Americans listened to a podcast, with over 30% tuning in to podcasts on at least a monthly basis. This is a sharp increase from years prior and is a trend reflected around the world, with podcasts increasing in popularity in all languages. With Meltwater’s new podcast integration, we are adding over 3,000 new podcasts to the platform every day, from over a dozen languages.

Meltwater customers can now monitor podcasts for all the keywords that are important to them. Additionally, they can surface opportunities to place thought leaders from their organization on podcasts that cover topics relevant to their expertise.

Having the ability to monitor podcasts globally allows our customers to benchmark their presence on podcasts against their competitors, understand the sentiment of every mention, analyze their overall performance, and share relevant podcasts with stakeholders easily.

Rounding out a complete all-in-one solution, customers can monitor and analyze podcasts alongside online news, print media, broadcast coverage, and social media. Now, more than ever, they can rest assured that Meltwater will capture more content and conversations than anyone else in the industry.

“The consumer popularity of podcasts is steadily increasing around the world, and companies are now turning their attention to podcasts as an important medium for them to consider as a part of their Public Relations and Marketing strategy. We are excited to add podcast monitoring to the solutions that we deliver to our customers, and to help them gain insights from podcasts to see how that corresponds with what’s being said in the news and all across social media,” said Niklas de Besche, Executive Director of Product at Meltwater.

Meltwater customers can speak to their Account Manager to add podcast monitoring to their subscription, and more information on the new podcast monitoring integration can be found here.

About Meltwater

Meltwater, a pioneer of media intelligence and now Outside Insight, gives businesses the information advantage they need to stay ahead. More than 32,000 companies use Meltwater’s media intelligence to stay on top of billions of online conversations and extract relevant insights to manage their brands strategically. With nearly 20 years of experience analyzing data, Meltwater is dedicated to personal, global service built on the local expertise of 55 offices across six continents. Meltwater is also committed to fostering the data science ecosystem through MEST, a pan-African entrepreneurial program & incubator, and Shack15, a global data science community. Learn more at meltwater.com.

Media contact:

Johnny Vance

Global Head of Product Marketing and Partnerships

johnny.vance@meltwater.com

Teledyne DALSA’s 32k TDI camera delivers the industry’s highest resolution in line scan imaging

Patent-pending pixel offset technology outputs 32k resolution for enhanced detectability

Teledyne DALSA’s new Linea HS 32k line scan camera

New Linea HS CMOS TDI model delivers up to 150 kHz line rate and helps to lower system costs

WATERLOO, Ontario, Feb. 20, 2020 (GLOBE NEWSWIRE) — Teledyne DALSA, a Teledyne Technologies [NYSE:TDY] company and global leader in machine vision technology, is pleased to announce the release of its newest charge-domain CMOS TDI camera – the Linea HS 32k TDI camera using patent-pending pixel offset technology.

“One of the greatest challenges in machine vision today is to increase resolution while maintaining or even reducing system-level costs. Our new Linea HS 32k TDI camera provides an innovative solution to meet such contradictory requirements. OEMs can readily integrate the new camera into existing systems to achieve much higher performance without needing to change any components,” said Xing-Fei He, Senior Product Manager for Teledyne DALSA’s line scan portfolio.

The Linea HS 32k uses two 16k/5μm TDI arrays with pixel offset. Two 16k/5μm images are captured in real time, then reconstructed to achieve a higher resolution image of 32k/2.5μm. This upconversion significantly enhances detectability for subpixel defects. One advantage of the patent-pending pixel offset technology is that existing lighting and 16k/5μm lenses can be used without sacrifice in responsivity and MTF with a smaller physical pixel size.

Combined with Teledyne’s Xtium™2 CLHS series of high-performance frame grabbers, these new products represent a breakthrough in data throughput. Built on field-proven technology, the next generation CLHS fiber optic interface provides reliable and high throughput data transmission. Fiber optic cables lower system costs, offer longer cable lengths (up to 300 m), are immune to electromagnetic radiation in industrial environments. Teledyne DALSA’s Xtium2 family of high-performance frame grabbers feature the PCI Express Gen 3 x8 platform.

Key Features:

  • Up to 150 kHz line rate in 32k/2.5um resolutions, or 5 Gpix/sec
  • Compatible with existing lighting and lenses for 16k/5μm
  • Very low noise and high sensitivity
  • Active pixel assisted alignment
  • Camera Link HS fiber optic interface for high reliability and long cable data transmission
  • Lowers system costs

Please visit the Linea HS product page for more information. For sales enquiries, visit our contact page, and for full resolution images, our online media kit.

About Teledyne DALSA
Teledyne DALSA is a part of the Teledyne Imaging group and a leader in the design, manufacture and deployment of digital imaging components for machine vision. Teledyne DALSA image sensors, cameras, smart cameras, frame grabbers, software, and vision solutions are at the heart of thousands of inspection systems around the world and across multiple industries. For more information, visit www.teledynedalsa.com/imaging.

Teledyne Imaging is a group of leading-edge companies aligned under the Teledyne umbrella. Teledyne Imaging forms an unrivalled collective of expertise across the spectrum with decades of experience. Individually, each company offers best-in-class solutions. Together, they combine and leverage each other’s strengths to provide the deepest, widest imaging and related technology portfolio in the world. From aerospace through industrial inspection, scientific research, spectroscopy, radiography and radiotherapy, geospatial surveying, and advanced MEMS and semiconductor solutions, Teledyne Imaging offers worldwide customer support and the technical expertise to handle the toughest tasks. Their tools, technologies, and vision solutions are built to deliver to their customers a unique and competitive advantage.

All trademarks are registered by their respective companies.
Teledyne Imaging reserves the right to make changes at any time without notice.

Media Contact:
Geralyn Miller
Senior Manager, Global Media Relations
Tel: +1-519-886-6001 ext. 2187
Email: geralyn.miller@teledyne.com

Sales Contacts:

Sales.americas@teledynedalsa.com
Sales.europe@teledynedalsa.com
Sales.asia@teledynedalsa.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/01f9a9e6-36ae-4cf7-b162-0f92a062b08a

Nikkiso Cryogenic Services and Taikkiso Co., Ltd. Establish New Service Agreement

IRVINE, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) — Cryogenic Industries Service Companies (NCS), a functional unit of Nikkiso Cryogenic Industries’ Clean Energy and Industrial Gases Group (“Group”), has entered into a Collaboration Agreement with Taikkiso Co., Ltd. of Taiwan to become an ACD Authorized Sales and Service agent for the Taiwan market. Taikkiso has a special strong and long relationship in Taiwan in the pump business, and recently the UV-LED business, and holds a minor share of Nikkso Co., Ltd. The new collaboration will improve ACD’s presence in Asia and strengthen the Nikkiso Service Brand globally to 18 worldwide service locations. The Taikkiso facility will be fully operational by May 1, 2020.

The Agreement provides stronger regional coverage by offering more certified locations and certified field service technicians closer to ACD’s customers. The additional coverage also reduces customer downtime by providing quick service tech dispatch and a dedicated inventory guaranteeing parts availability.

James Estes, President of Nikkiso Cryogenic Services said, “Nikkiso is committed to strengthening the aftermarket services for all Nikkiso products worldwide. This alliance will enable us to better support the aftermarket service requirements for our customers, and deliver the highest quality service experience in Taiwan.”

The new center is located in Taiwan.

Services offered will include pump repair, oxygen cleaning, a pump exchange program, dedicated inventory, product training, and 24/7 customer support from certified technicians.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (a member of Nikkiso Co., Ltd.) member companies manufacture engineered cryogenic gas processing equipment and small-scale process plants for the liquefied natural gas (LNG), well services and industrial gas industries. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Cosmodyne and Cryoquip and a commonly-controlled group of approximately 20 operating entities.

For more information please visit www.cryoind.comwww.nikkisoCIservice.com and www.nikkiso.com.

MEDIA CONTACT:

Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

CoImmune, Inc. Announces FDA Approval of its IND Application to Conduct a Phase 2b Clinical Trial with CMN-001 in Advanced RCC Patients

DURHAM, N.C., Feb. 19, 2020 (GLOBE NEWSWIRE) — CoImmune, Inc. announced today that the FDA approved its investigational new drug application (IND) and that it is cleared to move forward with a Phase 2b clinical trial in advanced metastatic renal cell carcinoma (mRCC).

CMN-001, formerly known as AGS-003, is a dendritic cell-based immunotherapy custom matched to each patient’s particular disease. The rationale for the design of the randomized Phase 2b trial comes from a retrospective analysis of a prior clinical trial with CMN-001 involving more than 90 randomized subjects, where a strong synergy was observed with one of the approved drugs for treatment of mRCC. CoImmune scientists have discovered the molecular basis of the observed synergy and filed a patent application on this new mechanism of action for the combination therapy in January 2020.

This trial will recruit primarily poor risk mRCC patients. The clinical trial is being led by principle investigator Dr. Christopher G. Wood, Professor and Vice Chairman in the Department of Urology at the University of Texas MD Anderson Cancer Center in Houston, Texas. “Even with the latest and best available therapies, there is room for improvement in survival outcomes for high-risk mRCC patients. There is a good scientific rationale for conducting this Phase 2b trial and, if successful, CMN-001 may provide a further advance in the treatment of these patients,” stated Dr. Wood. CoImmune intends to initiate five clinical centers of excellence to participate in the trial and expects to treat the first patient in Q2 2020.

“We are very excited to be in a position to initiate the clinical trial with our lead product, CMN-001, just one year after starting up CoImmune,” said Dr. Charles Nicolette, chief executive officer of CoImmune. He added “Our prior clinical data and our new understanding of the mechanism of action of CMN-001 gives us confidence that we can reproduce the positive clinical signal previously observed.”

About CoImmune, Inc.

CoImmune specializes in the development of personalized immuno-oncology therapies including its lead candidate, CMN-001, for the treatment of metastatic renal cell carcinoma. CMN-001 is a dendritic cell-based, individualized immunotherapy that captures both mutated and variant antigens that are unique to each patient’s tumor, specifically designed to induce an immune response targeting the patient’s particular tumor antigens. CoImmune is also developing a clinical stage off-the-shelf CAR-T-like therapy for the treatment of acute lymphoblastic leukemia (ALL) in adult and pediatric patients.

For more information visit www.coimmune.com

Media Contact:

Lori Harrelson
CoImmune, Inc.
919-287-6349
lharrelson@coimmune.com